Introduction
Ticagrelor is an P2Y12 receptor antagonist, 1 which has been shown to reduce the combined endpoint of cardiovascular death, myocardial infarction, and stroke compared with clopidogrel in patients within the full spectrum of acute coronary syndromes (ACS) in the PLATO trial. 2 Since its introduction in 2011, Ticagrelor is increasingly used in Germany for the management of ACS. In the Guidelines of the European Society of Cardiology (ESC), its use is recommended in 2011 and 2015 for non-ST-elevation ACS 3, 4 and for ST-segment elevation myocardial infarction (STEMI) in 2013 and 2017 5, 6 with a Class 1 B recommendation. In addition the ESC guidelines recommend dual antiplatelet therapy (DAPT) for 12 months after ACS. type of P2Y12 receptor antagonist for various reasons. Little is known about the long-term persistence of DAPT including ticagrelor in real life. Therefore, it is of interest to collect information about the duration of DAPT with ticagrelor after ACS and to determine whether there is room for improvement. The ongoing percutaneous coronary intervention (PCI) registry of the German Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK) provides the opportunity to get access to a consecutive sample of patients who received peri-interventional therapy with ticagrelor. 8, 9 The Gemeinsamer Bundesausschuss (GBA) in
Germany has approved the use of ticagrelor for 12 months after ACS. 10 It is, therefore, of interest to determine the adherence to this recommendation and the reasons for premature discontinuation of ticagrelor and/or switching to alternative P2Y12 receptor antagonists.
Methods
The primary objective of the 'Real life long-term adherence to Ticagrelor after PCI for acute coronary syndromes' (REAL-TICA) study was to assess the long-term use of ticagrelor in patients with ACS and to evaluate the reasons for premature discontinuation of ticagrelor. It was a retrospective non-interventional study. Selected sites from the ALKK registry and the respective patients were identified. The sites' eligibility for this study included the frequent use (in more than 20%) of ticagrelor during the acute phase of ACS. Eligible patients were characterized by the diagnosis of ACS and the use of ticagrelor during PCI. Eligible sites were contacted by Institut für Herzinfarktforschung Ludwigshafen (IHF) and asked to contact their eligible patients by letter to obtain informed consent of the patients for the planned 12-month follow-up by IHF. A detailed questionnaire on events within the last 12 months, current symptoms, current medication, and the use of ticagrelor was added to the patients' letters. Patients then were asked to return their responses on consent to participate in the study as well as the filled in questionnaire to IHF. Alternatively, patients were able to choose to receive a telephone call by IHF to answer the detailed questionnaire in person.
In the standardized questionnaire myocardial infarction has been defined according to the criteria in the respective ESC Guidelines, [3] [4] [5] [6] stroke as persistent neurological deficit and bleeding as bleeding event leading to medical attention or cessation of antithrombotic therapy.
Statistics
Categorical data are presented as absolute numbers and percentages, metrical data as medians with 25th and 75th percentiles. The distribution of binary or nominal categorical variables was compared between patient groups by Pearson v 2 test, that of metrical and ordinal variables by Mann-Whitney test. Reported events during follow-up occurring not later than 12 months after index discharge were considered in the analysis. Rates of these rare events were compared using the Fisher's exact test. The descriptive statistics are based on the available cases. Discontinuation of Ticagrelor was defined as premature or early, if it took place not later than 270 days after the index procedure or was triggered by a reported bleeding event. The predictors for early discontinuation were analysed in a logistic regression model. Backward variable selection was performed including male sex and the following clinically relevant variables that were statistically significant in the unifactorial comparisons: age >75 years, prior stroke, prior oral anticoagulation, chronic kidney disease, STEMI, and cardiac surgery subsequent to the index intervention.
A P-values < _0.05 were considered significant without adjustment for multiple testing. All P-values are results of two-tailed tests. The statistical computations were performed using SAS release 9.3 on a personal computer (SAS Institute, Inc., Cary, NC, USA).
Results
A total of 3842 patients with ACS from 15 hospitals of the ALKK PCI-registry were identified as eligible for the REAL-TICA registry and were then contacted by mail by the participating site that treated the index ACS and were invited to participate.
Among those invited, 700 (18.2%) patients or relatives responded to the invitation, and 3142 patients were classified as nonresponders. Among the 700 responders, 654 patients were still alive, provided written informed consent to participate and completed the follow-up (by either returning a filled-in questionnaire or per interview by phone), and 46 patients were reported to have died (information provided by relatives or residents' registration office). The flow chart of patients is shown in Figure 1 .
The baseline characteristics of responders (patients with follow-up) and non-responders (patients without follow-up) are shown in Table 1 . There were differences between the two groups for age, gender, prior stroke, atrial fibrillation, hypertension, and type of ACS. However, the responder group seems representative for patients receiving ticagrelor during the acute phase of ACS in Germany. Information about the duration of ticagrelor treatment was available in 614 patients.
In total, 133 of 614 patients (21.7%) discontinued ticagrelor prematurely: nine patients (1.5%) discontinued ticagrelor before discharge, and 124 (20.2%) at a mean of 131 days after the index PCI.
PaƟents treated with Ɵcagrelor during the acute phase of ACS n=3842
PaƟents with informed consent and informaƟon on treatment duraƟon of Ɵcagrelor n=614
PaƟents not responding to the invitaƟon to parƟcipate n=3142
PaƟents without informaƟon about the duraƟon of Ɵcagrelor n=86 The time course of premature discontinuation of ticagrelor is depicted in Figure 2 .
We performed a multivariate analysis for the baseline characteristics, which were associated with premature discontinuation of ticagrelor and identified age >75 years, prior stroke, and atrial fibrillations as independent predictors of premature discontinuation ( Table 2) . Table 3 summarizes the reasons for premature discontinuation. Side effects leading to a premature discontnuation of ticagrelor were reported in less than 3% of the total patient population, while bleeding was the reason in 12 patients (1.9%). The person responsible for discontinuation was the general practioner in 51.4%, the hospital in 29.0%, the cardiologist in 12.1%, the patient in 2.4%, and unknown in 4.8%.
In 50% of patients stopping ticagrelor early no alternative antithrombotic therapy was given, while it has been replaced by clopidogrel in 28%, by prasugrel in 7%, and by oral anticoagulation in 8% ( Table 4) .
The clinical ischaemic and bleeding events in patients surviving 12 months with and without discontuation are shown in Table 5 . There were more bleedings and more patients with coronary artery bypass grafting (CABG) surgery in patients with early discontinuation. In patients with bleedings during follow-up (n = 25) almost 50% (n = 12) discontinued ticagrelor. In these 25 patients, there was no 
Discussion
The present analysis is one of the first reports about the adherence to DAPT with ticagrelor in patients with ACS treated with PCI in real life. The major finding is that ticagrelor is prematurely discontinued before the recommended 12-month duration in one of five patients. Patient related factors associated with premature discontinuation were age >75 years, previous stroke, and atrial fibrillation. Patients with atrial fibrillation and ACS usually have a CHA 2 DS 2 -VASc score of > _2, and therefore, an indication for chronic anticoagulation. Current guidelines recommend clopidogrel and not ticagrelor or prasugrel as part of combination therapy, 7 therefore, this finding is not unexpected.
For patients with higher age and/or previous stroke treating physicans might feel, that the increased risks for total bleeding complications and intracranial bleedings are not acceptable, and therefore, tend to limit the duration of DAPT with ticagrelor or switch to clopidogrel.
In the large international registry APTOR registry about 25% of patients with ACS receiving clopidogrel at discharge had discontinued clopidogrel prematurely before the end of the 12-month follow-up. 11 In a more recent report from another international registry, these data were almost identical with about 25% of patients stopping DAPT before 12 months, with a large variation beween countries. 12 In a study from Norway about 80% of patients were still on DAPT with ticagrelor 9 months after PCI for ACS, 13 in line with findings from Finland in which about 75% of patients were still on DAPT with ticagrelor after 12 months.
14 In a Belgian registry, 15 treatment persistence of DAPT with ticagrelor or prasugrel was higher after 12 months compared with DAPT with clopidogrel (80% vs. 80% vs. 59%, respectively). The TRANSLATE-ACS registry reports about an early cessation rate of 21.0% with clopidogrel and 23.2% with prasugrel within the first year after myocardial infarction, which was associated with an increase of adverse events. 16 Planned de-escalation of DAPT has been studied in two recent studies TOPIC and TROPICAL-ACS. to define the best strategy and timepoint for planned P2Y12 deescalation therapy after ACS. The most detailed informations about adherence to ticagrelor after ACS derive from the PLATO trial. 2 In this double-blind randomized trial, 23.4% of patients discontinued ticagrelor early. Therefore, our real-world findings support the results of the PLATO trial. Adverse events were the reason for discontinuation of ticagrelor in PLATO in 7.4%. In our study suspected side effects such as bradycardia or dyspnoea or the cause for premature discontinuation in less than 3% of patients. These findings are somewhat higher compared with the results of the PLATO trial, where 0.9% stopped ticagrelor because of dyspnoea. In our study bleedings were reported more often in patients with premature discontinuation and almost 50% of patients with bleeding discontinued ticagrelor. In PLATO after a bleeding event, there was no difference between treatment groups in the number of patients who discontinued randomized therapy as a result of the bleed. 19 After a PLATO major bleeding event, there were 8.1% patients who discontinued ticagrelor, and 8.9% who discontinued clopidogrel. Similarly, after experiencing PLATO major or minor bleeding, the rates of drug discontinuation were identical in both arms (10.8%). Following a TIMI major non-CABG related bleeding event 34.3%, and 31.4% of patients discontinued clopidogrel and ticagrelor. In our study 6/25 (24%) patients with bleeding discontinued ticagrelor and another 6/25 (24%) switched to clopidogrel. Further research is needed to evaluate the optimal antithrombotic strategy in patients with bleeding under DAPT, since premature discontinuation of DAPT has been shown to be associated with an increase in ischaemic events. 20 Initiatives such as the PRO-ACOR study 21 where adherence rates were closely monitored might be helpful to increase adherence to secondary prevention therapies after acute myocardial infarction.
Limitations
This was a retrospective study and only about 20% of eligible patients responded. However, there were no major differences between patients with and without follow-up. Despite this fact a higher premature discontinuation rate cannot be ruled out if a larger rate of the total population would have been included. The definite reason for discontinuation was not evaluable in about 40% of patients, leaving some uncertainty about true reason to discontinue ticagrelor, but side effects of ticagrelor and bleedings were specifically asked for and completely registered. The study was not powered to detect any differences in clinical events between patients with and without premature discontinuation of ticagrelor. Since the study did not include patients with initial medical management or patients undergoing CABG during the index hospital stay, the results cannot be extrapolated to these patients. Finally, the results were obtained in Germany only, so premature discontinuations rates of ticagrelor might vary in other European countries or even outside Europe.
Conclusions
In this real-life experience of ticagrelor in patients with ACS 22% of patients discontinued ticagrelor early. Side effects were the cause for discontinuation in only 3%, while age >75 years, prior stroke, atrial fibrillation, CABG, and bleeding during follow-up were associated with premature discontinuation. 
